Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis | Zendy

Vera M. R. Heydendael | Zendy; Phyllis I. Spuls | Zendy; Brent C. Opmeer | Zendy; Corianne A.J.M. de Borgie | Zendy; Johannes B. Reitsma | Zendy; Wouter F.M. Goldschmidt | Zendy; Patrick M. Bossuyt | Zendy; Jan D. Bos | Zendy; Menno A. de Rie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis

Author(s) -

Vera M. R. Heydendael,

Phyllis I. Spuls,

Brent C. Opmeer,

Corianne A.J.M. de Borgie,

Johannes B. Reitsma,

Wouter F.M. Goldschmidt,

Patrick M. Bossuyt,

Jan D. Bos,

Menno A. de Rie

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa021359

Subject(s) - medicine , methotrexate , psoriasis , psoriasis area and severity index , randomization , randomized controlled trial , ciclosporin , chemotherapy , gastroenterology , severity of illness , surgery , dermatology

Methotrexate and cyclosporine are well-known systemic therapies for moderate-to-severe chronic plaque psoriasis. We conducted a randomized, controlled trial comparing methotrexate and cyclosporine in terms of effectiveness, side effects, and the quality of life.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research